Effectiveness of a Condensed Protocol for Disclosing APOE Genotype and Providing Risk Education for Alzheimer Disease
Overview
Affiliations
Purpose: Brief, effective models of patient genetic education are needed for common, complex diseases. Using Alzheimer disease as a model, we compared participants' risk knowledge and recall in extended versus condensed education protocols.
Methods: A four-site randomized clinical trial enrolled 280 first-degree relatives of individuals with Alzheimer disease (mean age = 58 years, 71% female); each received lifetime Alzheimer disease risk information (range: 13-74%) that incorporated apolipoprotein E genotype. In the condensed protocol, participants received an educational brochure in place of an in-person education session. Outcomes were assessed at 6 weeks and 6 months following risk disclosure.
Results: The condensed protocol required less clinician time than the extended protocol (mean = 34 min vs. 77 min). The groups did not differ on recall of apolipoprotein E genotype or lifetime risk, and most participants in both groups recalled and retained this information over time. Both groups showed improvement from baseline in Alzheimer disease risk knowledge (e.g., understanding the magnitude of apolipoprotein E genotype effect on risk).
Conclusion: A condensed protocol for communicating genetic risk for Alzheimer disease achieved similar educational results as an extended protocol in this study. Further research should explore the efficacy of brief genetic education protocols for complex diseases in diverse populations.
Wolf S, Green R Annu Rev Genomics Hum Genet. 2023; 24:393-414.
PMID: 36913714 PMC: 10497726. DOI: 10.1146/annurev-genom-101122-103209.
Mozersky J, Roberts J, Rumbaugh M, Chhatwal J, Wijsman E, Galasko D J Alzheimers Dis. 2022; 90(3):1035-1043.
PMID: 35404285 PMC: 9794032. DOI: 10.3233/JAD-220113.
Patel H, Henrikson N, Ralston J, Leppig K, Scrol A, Jarvik G AMIA Annu Symp Proc. 2022; 2021:950-958.
PMID: 35309003 PMC: 8861684.
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
Ketchum F, Chin N, Grill J, Gleason C, Erickson C, Clark L Alzheimers Dement. 2022; 18(10):1969-1979.
PMID: 35213786 PMC: 9402800. DOI: 10.1002/alz.12620.
Pavarini G, Hamdi L, Lorimer J, Singh I Eur J Med Genet. 2021; 64(6):104180.
PMID: 33781925 PMC: 8192412. DOI: 10.1016/j.ejmg.2021.104180.